Malcolm Hoffman
Analyst
BMO Capital Markets
Analyst
BMO (on behalf of Evan Seigerman)
Equibles does not estimate personal net worth.
About Malcolm Hoffman
Malcolm Hoffman is recorded as Analyst at BMO Capital Markets and Analyst at BMO (on behalf of Evan Seigerman). Malcolm Hoffman has spoken on 11 earnings calls across 7 companies, most recently for Neurocrine Biosciences Inc on November 2, 2026. Those appearances were for AbCellera Biologics Inc. (ABCL), Axsome Therapeutics, Inc. (AXSM), Acadia Pharmaceuticals Inc (ACAD), Neurocrine Biosciences Inc (NBIX), AbbVie Inc. (ABBV) and 2 other companies. The companies whose calls Malcolm Hoffman spoke on are classified in the Healthcare sector.
Malcolm Hoffman on recent calls
“I wanted to touch again on the muscarinx that you have in your pipeline. I saw that you had discontinued 986, the M4 antagonist for movement disorders. And I was just wondering if If you could give a little bit of color.”
“Tourette's syndrome was noted as an opportunity for AXS20 previously, but seems to be removed from the pipeline slide today. Does that reflect a formal development decision or just prioritization of schizophrenia?”
“You highlighted some pretty strong growth in NBRX for availability in the 65-plus patient group there. Can you maybe break this out further to indicate how much of this may be driven by agitation versus MDD expansion as well?”
“I was wondering if you could provide any color on whether you have seen a normalization of typical refill rates for a new positive. I know you had mentioned new patient starts are really strong, but just wanted to get a sense whether recurring scripts are back on track.”
Affiliation history
-
BMO Capital Markets
Analyst
Source not stated
Current -
BMO (on behalf of Evan Seigerman)
Analyst
Source not stated
Current
Company network
Drug Manufacturers - Specialty & Generic · Healthcare
ABBV
Drug Manufacturers - General · Healthcare
Drug Manufacturers - General · Healthcare